Alpine Global Management’s Ionis Pharmaceuticals IONS Stock Holding History

Alpine Global Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,600	Closed	-$4.24M	–	328
2025 Q4	$4.24M	Sell	53,600 -2,300	-4%	-$173K	0.91%	22
2025 Q3	$3.66M	Buy	55,900 +30,463	+120%	+$1.49M	0.74%	27
2025 Q2	$1.01M	Sell	25,437 -2,660	-9%	-$87K	0.23%	64
2025 Q1	$848K	Buy	+28,097	New	+$920K	0.22%	66
2020 Q1	–	Sell	-7,474	Closed	-$452K	–	339
2019 Q4	$452K	Buy	+7,474	New	+$445K	0.1%	177
2016 Q1	–	Sell	-20,609	Closed	-$1.28M	–	175
2015 Q4	$1.28M	Buy	+20,609	New	+$1.11M	0.41%	45
2015 Q3	–	Sell	-6,676	Closed	-$384K	–	446
2015 Q2	$384K	Buy	+6,676	New	+$424K	0.06%	222

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpine Global Management's IONS Position: Q1 2026 in Review

Alpine Global Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 53,600 shares — an estimated $4.24M sold.

Alpine Global Management first reported a position in IONS in Q2 2015 and held it in 7 quarters. The position peaked at $4.24M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Alpine Global Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Alpine Global Management sold 53,600 Ionis Pharmaceuticals shares in Q1 2026, an estimated $4.24M.
Alpine Global Management first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Alpine Global Management's Ionis Pharmaceuticals position peaked at $4.24M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Alpine Global Management's 13F filing for Q1 2026, filed 15 May 2026.